Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma

BackgroundThe treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM. The study is aim to evaluate the cost-effectiv...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Zhuo-miao Ye, Zi-Qing Tang, Zhe Xu, Qin Zhou, Huan Li
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-07-01
Saila:	Frontiers in Public Health
Gaiak:	cost-effectiveness nivolumab ipilimumab malignant pleural mesothelioma Markov model
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fpubh.2022.947375/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!